4basebio reports 210% rise in H1 sales orders amid revenue decline

4basebio PLC, a synthetic DNA manufacturer for genomic medicines based in Cambridge, UK, reported a substantial 210% increase in sales orders for the first half of 2026 compared to the same period last year, with orders totaling £1.2 million. However, revenue for the period fell to £0.3 million from £1.2 million in H1 2025, primarily due to project delays caused by market headwinds and a significant contract from a large clinical pharmaceutical.

The company reported a loss of £8.9 million for H1 2026, up from £7.8 million in the previous period, while cash outflow from operations increased to £8.4 million, up from £8.2 million. Cash reserves were £14.1 million at the end of the period, down from £17.8 million at the end of 2025, and the company drew on a loan facility of €7 million provided by 2Invest AG to extend its cash runway into late 2027.

Despite the revenue decline, 4basebio still has a qualified business pipeline worth £63 million, which has increased six-fold since Q3 2025. The company has secured a clinical supply agreement for a Phase 2 clinical trial and signed a collaboration with Genezen, a viral vector contract development and manufacturing organization.

Additionally, 4basebio extended an existing relationship with a pharmaceutical customer to support a Phase 1 cell therapy program and launched new product offerings, including a single-stranded DNA platform and personalized cancer vaccines.